• +1-646-491-9876
    • +91-20-67278686

    Search

    Hereditary Angioedema Pipeline Review H1 2017

    Hereditary Angioedema Pipeline Review H1 2017

    • Report Code ID: RW0001858668
    • Category Pharmaceuticals
    • No. of Pages 90
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Hereditary Angioedema (HAE) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2017, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape.

    Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4, 10 and 2 respectively.

    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) .
    - The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development
    ActiveSite Pharmaceuticals Inc
    Adverum Biotechnologies Inc
    Arrowhead Pharmaceuticals Inc
    BioCryst Pharmaceuticals Inc
    Cevec Pharmaceuticals GmbH
    CSL Ltd
    Global Blood Therapeutics Inc
    iBio Inc
    Ionis Pharmaceuticals Inc
    Kalvista Pharmaceuticals Inc
    Pharming Group NV
    ProMetic Life Sciences Inc
    Shire Plc
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles
    ADVM-053 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AROF-12 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ATN-035 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ATN-249 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BCX-7353 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C1 esterase inhibitor (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C1 esterase inhibitor (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C1 esterase inhibitor (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C1 esterase inhibitor (recombinant) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C1 esterase inhibitor (recombinant) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CSL-312 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GBT-18713 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    icatibant acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IONIS-PKKLRx - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IONIS-PKKRx - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KVD-818 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lanadelumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SHP-623 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones
    Featured News & Press Releases
    May 25, 2017: BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial
    May 22, 2017: Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop
    May 18, 2017: Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial
    Apr 12, 2017: BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks
    Apr 04, 2017: New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients
    Mar 22, 2017: NEJM Publishes Pivotal Data on Preventing HAE Attacks
    Mar 16, 2017: Shire Receives European Approval for Label Extension of CINRYZE to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Pediatric Patients with HAE
    Mar 06, 2017: Attune Pharmaceuticals Announces Pre-Clinical Data for ATN-249, An Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at AAAAI
    Mar 01, 2017: Attune Pharmaceuticals Announces Late-Breaking Poster Presentation of ATN-249, an Oral Kallikrein Inhibitor for the Treatment of HAE
    Feb 27, 2017: BioCryst Reports Positive Interim Results from its APeX-1 Trial
    Feb 23, 2017: New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease
    Jan 16, 2017: European Commission amends Marketing Authorisation for RUCONEST to include self-administration
    Dec 15, 2016: CHMP Adopts Extension To Existing Therapeutic Indication For Cinryze
    Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL312 in Australia
    Nov 14, 2016: Pharming Announces the Presentation of the Results of the RUCONEST Phase II study for Prophylaxis of Hereditary Angioedema Attacks
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Adverum Biotechnologies Inc, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioCryst Pharmaceuticals Inc, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Cevec Pharmaceuticals GmbH, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Global Blood Therapeutics Inc, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by iBio Inc, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group NV, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ProMetic Life Sciences Inc, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Shire Plc, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, H1 2017
    Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    ActiveSite Pharmaceuticals Inc
    Adverum Biotechnologies Inc
    Arrowhead Pharmaceuticals Inc
    BioCryst Pharmaceuticals Inc
    Cevec Pharmaceuticals GmbH
    CSL Ltd
    Global Blood Therapeutics Inc
    iBio Inc
    Ionis Pharmaceuticals Inc
    Kalvista Pharmaceuticals Inc
    Pharming Group NV
    ProMetic Life Sciences Inc
    Shire Plc

    Request for Sample

    Report Url http://www.reportsweb.com//hereditary-angioedema-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hereditary-angioedema-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hereditary-angioedema-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments